Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2192588
Abstract: AIMS To estimate the health utilities and quality-adjusted life years (QALYs) in patients with amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE-ALS. MATERIALS AND METHODS We performed a post hoc analysis of clinical… read more here.
Keywords: health utilities; reldesemtiv; utilities quality; placebo ... See more keywords
MiToS and King’s staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial
Sign Up to like & getrecommendations! Published in 2022 at "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration"
DOI: 10.1080/21678421.2022.2154678
Abstract: Abstract Objective To evaluate the Milano-Torino staging (MiToS) and King’s staging systems as potential outcome measures for clinical trials in amyotrophic lateral sclerosis (ALS) by assessing these outcomes in FORTITUDE-ALS. Methods This was a post… read more here.
Keywords: mitos king; baseline; outcome measures; analysis ... See more keywords